Saturday 17 October 2026
Export ALZN’s income statement to Excel — free account
Alzamend Neuro, Inc.
ALZN Healthcare Biotechnology
In the quarter to July 2026, EPS grew 46.9% and free cash flow grew 51.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.32
0.04
+3.13%
Follow ALZN
| Older periods | Oct '25 | Jan '26 | Apr '26 | Jul '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(157.96%) | (267.82%) | (373.18%) | (163.23%) | |
| (127.12%) | (183.63%) | (262.55%) | (122.36%) | ||
ROIC |
0.00% | 0.00% | (24,352.50%) | 0.00% | |
Return on Tangible Assets |
(146.75%) | (345.36%) | (1,196.45%) | (156.77%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.67) | (1.57) | (2.42) | (1.53) | |
Free Cash Flow |
(5.65) | (5.96) | (8.07) | (6.84) | |
| Other line items | |||||
Cash ROIC |
(63.99%) | (121.68%) | (558.75%) | (51.09%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(772.97) | (1,019.55) | (1,348.75) | (1,515.35) | |
Operating CF/Net income |
0.88 | 0.79 | 0.92 | 0.75 | |
Depreciation/Fixed assets |
0.22 | 0.28 | 0.35 | 0.39 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.67) | (1.57) | (2.42) | (1.53) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates